Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01503021 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis
A Phase 3 study, sponsored by Rockwell Medical Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 718
- Enrollment target
NCT01503021 is a Phase 3 study that has completed, run by Rockwell Medical Technologies. The registered enrollment target is 718 participants.
The verdict
NCT01503021, a Phase 3 study, has completed, sponsored by Rockwell Medical Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 718 participants
- Enrollment target
Study Summary
The purpose of the parent study is to assess the short-term safety and tolerability of soluble ferric pyrophosphate (SFP) in dialysate administered to a large number of representative adult chronic kidney disease patients on hemodialysis (CKD-HD). The purpose of the extension study is to assess the long-term safety and tolerability of SFP.
Interventions
- OTHER Placebo
- DRUG SFP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 718 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01503021
The ClinicalTrials.gov registry entry for NCT01503021 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 718 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockwell Medical Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01503021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01503021 about?
NCT01503021 is a clinical study titled "Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis". The purpose of the parent study is to assess the short-term safety and tolerability of soluble ferric pyrophosphate (SFP) in dialysate administered to a large number of representative adult chronic kidney disease patients on hemodialysis (CKD-HD). The purpose of the extension study is to assess the...
What is the current status of trial NCT01503021?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 718 participants. The study started on 2011-11. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01503021?
The interventions under investigation include: Placebo (OTHER), SFP (DRUG).
Who is sponsoring clinical trial NCT01503021?
This trial is sponsored by Rockwell Medical Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.